|Bid||15.05 x 485800|
|Ask||15.30 x 241000|
|Day's range||15.00 - 15.32|
|52-week range||11.92 - 16.44|
|PE ratio (TTM)||46.24|
|Earnings date||26 Nov 2018|
|Forward dividend & yield||0.25 (1.65%)|
|1y target est||12.79|
I’ve been keeping an eye on Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) because I’m attracted to its fundamentals. Looking at the company as a whole, as a potential stockRead More...
This analysis is intended to introduce important early concepts to people who are starting to invest and want to begin learning about how to value company based on its currentRead More...
Robust, high-growth companies such as NZX are appealing to investors for many reasons. They bring about a strong upside to your portfolio, and less downside risk as opposed to financiallyRead More...
Building up an investment case requires looking at a stock holistically. Today I’ve chosen to put the spotlight on Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) due to its excellentRead More...
Fisher & Paykel Healthcare has won a patent case against rival medical products manufacturer ResMed, after a court in the United Kingdom ruled the patent claim invalid. In 2016, New Zealand-based Fisher & Paykel sought a declaration from the High Court that three of ResMed's European patents were invalid in the UK and should be revoked. ResMed revoked two of its patents in the UK just before the trial was due to start, but left one for consideration by the High Court's patents division.